Humacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runway
Source: SeekingAlpha
2025-08-11 10:01:36 ET
More on Humacyte
- Humacyte, Inc. (HUMA) Q2 2025 Earnings Call Transcript
- Humacyte: Revenue Ramp From Symvess Incoming
- Humacyte Paradoxically Scales Back As Symvess Begins Its Long Journey
- Humacyte GAAP EPS of -$0.24 misses by $0.08, revenue of $0.3M misses by $0.7M
- Humacyte rises on Symvess sale to military treatment facility
Read the full article on Seeking Alpha
For further details see:
Humacyte targets over 200 hospital access points for Symvess as VAC approvals surge and cost cuts extend cash runway
Humacyte Inc.
NASDAQ: HUMA
HUMA Trading
0.0% G/L:
$1.165 Last:
1,302,350 Volume:
$1.15 Open:
HUMA Latest News
February 18, 2026 08:00:00 am
Humacyte Announces Presentation of Symvess® Long-Term Safety and Efficacy Results at VESS Meeting
February 09, 2026 08:00:00 am
Humacyte Announces New U.S. Department of Defense Funding for Procurement of Bioengineered Blood Vessels
HUMA Stock Data
$220,166,898
198,988,939
0.6%
62
N/A
Biotechnology & Life Sciences
Healthcare
US
Durham
